Lotus Pharmaceutical has announced that its subsidiary, Alvogen Korea, has commenced distribution of Uro-Vaxom in South Korea following an agreement with OM Pharma.

• Commercial Transition: Alvogen Korea has assumed responsibility for local distribution under Lotus’ previously announced agreement to acquire the product rights in South Korea.
• Regulatory Timeline: The transfer of marketing authorisation to Alvogen Korea is expected to be completed in the fourth quarter of 2026.
• Product Profile: Uro-Vaxom is an oral immunoactive product for the prevention of recurrent urinary tract infections and is currently marketed in more than 40 countries.

This summary is based on a news article published by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.